In2cure’s founder has received SEK 950,000 from the Swedish Research Council for development of the drug candidate BioC, which will be used to promote wound healing. The In2cure project received consistently high scores in the Research Council’s assessment.
Funding has been allocated to the project “TCP-25 gel for prevention of wound infection – a proof of concept study.” The projects were ranked based on criteria such as level of innovation, quality, qualifications of the applicant and the potential impact of the project on its field.
“In2cure’s founder Artur Schmidtchen, who is researcher in the field, submitted the application. We are extremely proud that the project consistently received the two highest grades ‘excellent’ and ‘outstanding.’ The funds will take our drug candidate through substantial steps in the preclinical tests,” says Helene Hartman, CEO of In2cure.
Artur Schmidtchen is Professor of Dermatology and Venereology at Lund University and a physician at Skåne University Hospital. He has analyzed how endogenous peptides act to fight infection, reduce inflammation and deactivate the toxic substances that form when bacteria enter the body. In2cure is developing medications based on this research which will function without antibiotics.
In2cure is a startup company in SmiLe Incubator, which supports life science entrepreneurs with business development and access to well-equipped laboratories, and is located at Medicon Village in Lund, Sweden.
About In2cure: In2cure develops medications based on BioC, an endogenous peptide. As part of the body's immune system, BioC has been carefully analyzed, revealing that it suppresses inflammation, prevents infection and neutralizes endotoxins. BioCure is a platform for the development of modern medications for the post-antibiotics era. As a first application, in2cure is developing a wound treatment gel, with plans to initiate clinical studies in late 2019.